CN113498342A - 参与协同结合的化合物和其用途 - Google Patents

参与协同结合的化合物和其用途 Download PDF

Info

Publication number
CN113498342A
CN113498342A CN201980092760.0A CN201980092760A CN113498342A CN 113498342 A CN113498342 A CN 113498342A CN 201980092760 A CN201980092760 A CN 201980092760A CN 113498342 A CN113498342 A CN 113498342A
Authority
CN
China
Prior art keywords
alkyl
optionally substituted
compound
ring
pharmaceutically acceptable
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201980092760.0A
Other languages
English (en)
Chinese (zh)
Inventor
M·金
N·珀尔
A·科尔曼
N·殷
J·T·罗
J·Y·安
M·J·穆尔维希尔
E·S·科尔屯
A·L·吉尔
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ruixin Pharmaceutical Co
Original Assignee
Ruixin Pharmaceutical Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ruixin Pharmaceutical Co filed Critical Ruixin Pharmaceutical Co
Publication of CN113498342A publication Critical patent/CN113498342A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D498/18—Bridged systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/5025—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/504—Pyridazines; Hydrogenated pyridazines forming part of bridged ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D237/00—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
    • C07D237/02—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings
    • C07D237/04—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having less than three double bonds between ring members or between ring members and non-ring members
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/08—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing alicyclic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains three hetero rings
    • C07D487/18—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/22—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains four or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Saccharide Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Steroid Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
CN201980092760.0A 2018-12-21 2019-12-20 参与协同结合的化合物和其用途 Pending CN113498342A (zh)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US201862783816P 2018-12-21 2018-12-21
US62/783816 2018-12-21
US201962894493P 2019-08-30 2019-08-30
US62/894493 2019-08-30
US201962930489P 2019-11-04 2019-11-04
US62/930489 2019-11-04
PCT/US2019/068100 WO2020132597A1 (en) 2018-12-21 2019-12-20 Compounds that participate in cooperative binding and uses thereof

Publications (1)

Publication Number Publication Date
CN113498342A true CN113498342A (zh) 2021-10-12

Family

ID=71099011

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201980092760.0A Pending CN113498342A (zh) 2018-12-21 2019-12-20 参与协同结合的化合物和其用途

Country Status (14)

Country Link
US (2) US20200197391A1 (https=)
EP (1) EP3897644A4 (https=)
JP (2) JP7721052B2 (https=)
KR (1) KR20210116479A (https=)
CN (1) CN113498342A (https=)
AU (2) AU2019401466B2 (https=)
BR (1) BR112021012057A2 (https=)
CA (1) CA3123869A1 (https=)
IL (2) IL284210B2 (https=)
MX (2) MX2021007468A (https=)
SA (1) SA521422304B1 (https=)
SG (1) SG11202106605VA (https=)
TW (1) TW202600561A (https=)
WO (1) WO2020132597A1 (https=)

Cited By (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN116284045A (zh) * 2023-05-18 2023-06-23 西南交通大学 一种手性吲哚单元取代的四氢异喹啉化合物及其合成方法
CN116570599A (zh) * 2023-07-04 2023-08-11 四川大学华西医院 Vs6766联合lxh254的应用及药物组合物
CN117720556A (zh) * 2022-09-19 2024-03-19 杭州阿诺生物医药科技有限公司 一种pan-KRAS抑制剂化合物及其制备方法和用途
WO2024060966A1 (zh) * 2022-09-19 2024-03-28 杭州阿诺生物医药科技有限公司 一种pan-KRAS抑制剂化合物
WO2024067857A1 (zh) * 2022-09-29 2024-04-04 南京明德新药研发有限公司 大环衍生物及其应用
CN118373832A (zh) * 2023-01-20 2024-07-23 深圳晶蛋生物医药科技有限公司 大环类化合物、其药物组合物及其应用
WO2025162395A1 (zh) * 2024-02-01 2025-08-07 山东先声生物制药有限公司 吲哚衍生物作为ras抑制剂及其应用
WO2025214350A1 (en) * 2024-04-08 2025-10-16 Sunrise Oncology (Hong Kong) Limited Macrocyclic compounds as ras inhibitors for the treatment of cancer
WO2026046393A1 (zh) * 2024-09-02 2026-03-05 山东先声再明生物制药有限公司 吲哚类衍生物的制备及其应用

Families Citing this family (55)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW201629069A (zh) * 2015-01-09 2016-08-16 霍普驅動生物科技股份有限公司 參與協同結合之化合物及其用途
EP4302834A3 (en) 2016-07-12 2024-07-17 Revolution Medicines, Inc. 2,5-disubstituted 3-methyl pyrazines and 2,5,6-trisubstituted 3-methyl pyrazines as allosteric shp2 inhibitors
JP7240319B2 (ja) 2017-01-23 2023-03-15 レヴォリューション・メディスンズ，インコーポレイテッド アロステリックｓｈｐ２阻害剤としての二環式化合物
KR20190110588A (ko) 2017-01-23 2019-09-30 레볼루션 메디슨즈, 인크. 알로스테릭 shp2 억제제로서의 피리딘 화합물
TW201930292A (zh) 2017-10-12 2019-08-01 美商銳新醫藥公司 作為變構ｓｈｐ２抑制劑的吡啶、吡嗪和三嗪化合物
JP7361693B2 (ja) 2017-12-15 2023-10-16 レヴォリューション・メディスンズ，インコーポレイテッド アロステリックｓｈｐ２阻害剤としての多環式化合物
BR112021012057A2 (pt) * 2018-12-21 2021-10-19 Revolution Medicines, Inc. Compostos que participam de ligação cooperativa e usos dos mesmos
AU2020377925A1 (en) 2019-11-04 2022-05-05 Revolution Medicines, Inc. Ras inhibitors
TW202132316A (zh) * 2019-11-04 2021-09-01 美商銳新醫藥公司 Ｒａｓ抑制劑
IL322454A (en) * 2019-11-04 2025-09-01 Revolution Medicines Inc ras inhibitors
US20210322405A1 (en) * 2020-04-15 2021-10-21 Washington University Compositions and methods for treating cancer
IL299131A (en) 2020-06-18 2023-02-01 Revolution Medicines Inc Methods for delaying, preventing and treating acquired resistance to RAS inhibitors
US20250195521A1 (en) 2020-09-03 2025-06-19 Revolution Medicines, Inc. Use of sos1 inhibitors to treat malignancies with shp2 mutations
CA3194067A1 (en) 2020-09-15 2022-03-24 Revolution Medicines, Inc. Ras inhibitors
WO2022133037A1 (en) * 2020-12-17 2022-06-23 Blossomhill Therapeutics, Inc. Macrocycles and their use
CN116635076A (zh) * 2020-12-17 2023-08-22 荣山医药股份有限公司 大环化合物及其用途
MX2023011608A (es) * 2021-04-02 2023-12-14 Massachusetts Gen Hospital Metodos para inhibir ras.
US20240217960A1 (en) * 2021-04-09 2024-07-04 Universität Basel Triazine derivative as covalent inhibitors of pi3k
KR20240017811A (ko) * 2021-05-05 2024-02-08 레볼루션 메디슨즈, 인크. 암의 치료를 위한 ras 억제제
JP2024516450A (ja) 2021-05-05 2024-04-15 レボリューション メディシンズ インコーポレイテッド 共有結合性ｒａｓ阻害剤及びその使用
TW202309052A (zh) 2021-05-05 2023-03-01 美商銳新醫藥公司 Ｒａｓ抑制劑
AU2022281343A1 (en) 2021-05-25 2023-11-30 Revolution Medicines, Inc. Methods for inhibiting ras
US12280055B2 (en) 2021-05-27 2025-04-22 Mirati Therapeutics, Inc. Combination therapies
WO2023015559A1 (en) * 2021-08-13 2023-02-16 Nutshell Biotech (Shanghai) Co., Ltd. Macrocycle compounds as inhibitors of ras
AR126854A1 (es) 2021-08-27 2023-11-22 Hoffmann La Roche Compuestos macrocíclicos para el tratamiento de cáncer
AR127308A1 (es) 2021-10-08 2024-01-10 Revolution Medicines Inc Inhibidores ras
CN119212994A (zh) 2021-12-17 2024-12-27 建新公司 作为shp2抑制剂的吡唑并吡嗪化合物
EP4227307A1 (en) 2022-02-11 2023-08-16 Genzyme Corporation Pyrazolopyrazine compounds as shp2 inhibitors
JP2025510572A (ja) 2022-03-08 2025-04-15 レボリューション メディシンズ インコーポレイテッド 免疫不応性肺癌を治療するための方法
CN119156393A (zh) * 2022-04-25 2024-12-17 翰森生物有限责任公司 环状化合物及其制备方法和医药用途
JP2025519199A (ja) 2022-06-01 2025-06-24 エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト がんの治療のためのハロインドール大環状化合物
WO2023240263A1 (en) 2022-06-10 2023-12-14 Revolution Medicines, Inc. Macrocyclic ras inhibitors
CN120813588A (zh) 2023-02-14 2025-10-17 豪夫迈·罗氏有限公司 用于治疗癌症的三环化合物
AU2024241633A1 (en) 2023-03-30 2025-11-06 Revolution Medicines, Inc. Compositions for inducing ras gtp hydrolysis and uses thereof
AR132338A1 (es) 2023-04-07 2025-06-18 Revolution Medicines Inc Inhibidores de ras
CR20250420A (es) 2023-04-07 2025-11-20 Revolution Medicines Inc Inhibidores macrocíclicos de ras
CN121464140A (zh) 2023-04-14 2026-02-03 锐新医药公司 Ras抑制剂的结晶形式、含有其的组合物及其使用方法
CN121100123A (zh) 2023-04-14 2025-12-09 锐新医药公司 Ras抑制剂的结晶形式
KR20260027943A (ko) * 2023-05-26 2026-03-03 레볼루션 메디슨즈, 인크. Ras 억제제
US20250049810A1 (en) 2023-08-07 2025-02-13 Revolution Medicines, Inc. Methods of treating a ras protein-related disease or disorder
AU2024360465A1 (en) 2023-10-12 2026-04-09 Revolution Medicines, Inc. Macrocyclic ras inhibitors
WO2025090809A1 (en) * 2023-10-25 2025-05-01 Kumquat Biosciences Inc. Macrocyclic heterocycles and uses thereof
CN117567483B (zh) * 2023-11-23 2025-10-21 济南市中心医院 一种通过金催化的不对称环加成反应及动力学拆分合成手性氮杂八元环类化合物的方法
WO2025171296A1 (en) 2024-02-09 2025-08-14 Revolution Medicines, Inc. Ras inhibitors
WO2025217307A1 (en) 2024-04-09 2025-10-16 Revolution Medicines, Inc. Methods for predicting response to a ras(on) inhibitor and combination therapies
TW202547461A (zh) 2024-05-17 2025-12-16 美商銳新醫藥公司 Ｒａｓ抑制劑
WO2025255438A1 (en) 2024-06-07 2025-12-11 Revolution Medicines, Inc. Methods of treating a ras protein-related disease or disorder
WO2025265060A1 (en) 2024-06-21 2025-12-26 Revolution Medicines, Inc. Therapeutic compositions and methods for managing treatment-related effects
WO2026006747A1 (en) 2024-06-28 2026-01-02 Revolution Medicines, Inc. Ras inhibitors
WO2026015790A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Methods of treating a ras related disease or disorder
WO2026015796A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Methods of treating a ras related disease or disorder
WO2026015825A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Use of ras inhibitor for treating pancreatic cancer
WO2026015801A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Methods of treating a ras related disease or disorder
WO2026050446A1 (en) 2024-08-29 2026-03-05 Revolution Medicines, Inc. Ras inhibitors
WO2026072904A2 (en) 2024-09-26 2026-04-02 Revolution Medicines, Inc. Compositions and methods for treating lung cancer

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070265333A1 (en) * 2006-05-11 2007-11-15 Hong Fu Macrocyclic kinase inhibitors
US20130344030A1 (en) * 2012-06-08 2013-12-26 Selcia Ltd. Macrocyclic inhibitors of flaviviridae viruses
US20140256717A1 (en) * 2011-05-19 2014-09-11 Centro Nacional De Investigaciones Oncológicas (Cnio) Macrocyclic compounds as protein kinase inhibitors

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9119853B2 (en) * 2010-02-09 2015-09-01 Neurovive Pharmaceutical Ab Sanglifehrin based compounds
IL269779B2 (en) * 2017-04-05 2026-04-01 Revolution Medicines Inc Methods and reagents for the analysis of protein-protein interfaces
BR112021012057A2 (pt) * 2018-12-21 2021-10-19 Revolution Medicines, Inc. Compostos que participam de ligação cooperativa e usos dos mesmos

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070265333A1 (en) * 2006-05-11 2007-11-15 Hong Fu Macrocyclic kinase inhibitors
US20140256717A1 (en) * 2011-05-19 2014-09-11 Centro Nacional De Investigaciones Oncológicas (Cnio) Macrocyclic compounds as protein kinase inhibitors
US20130344030A1 (en) * 2012-06-08 2013-12-26 Selcia Ltd. Macrocyclic inhibitors of flaviviridae viruses

Cited By (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2024060966A1 (zh) * 2022-09-19 2024-03-28 杭州阿诺生物医药科技有限公司 一种pan-KRAS抑制剂化合物
CN117720554A (zh) * 2022-09-19 2024-03-19 杭州阿诺生物医药科技有限公司 一种pan-KRAS抑制剂化合物及其制备方法和用途
CN117903169A (zh) * 2022-09-19 2024-04-19 杭州阿诺生物医药科技有限公司 一种pan-KRAS抑制剂化合物
CN117720556A (zh) * 2022-09-19 2024-03-19 杭州阿诺生物医药科技有限公司 一种pan-KRAS抑制剂化合物及其制备方法和用途
CN117720555A (zh) * 2022-09-19 2024-03-19 杭州阿诺生物医药科技有限公司 一种制备kras抑制剂化合物的中间体及其合成方法
US12458647B2 (en) 2022-09-29 2025-11-04 Guangzhou Joyo Pharmatech Co., Ltd. Macrocyclic derivative and use thereof
WO2024067857A1 (zh) * 2022-09-29 2024-04-04 南京明德新药研发有限公司 大环衍生物及其应用
CN118373832A (zh) * 2023-01-20 2024-07-23 深圳晶蛋生物医药科技有限公司 大环类化合物、其药物组合物及其应用
CN116284045A (zh) * 2023-05-18 2023-06-23 西南交通大学 一种手性吲哚单元取代的四氢异喹啉化合物及其合成方法
CN116570599B (zh) * 2023-07-04 2023-10-20 四川大学华西医院 Vs6766联合ly3009120的应用及药物组合物
CN116570599A (zh) * 2023-07-04 2023-08-11 四川大学华西医院 Vs6766联合lxh254的应用及药物组合物
WO2025162395A1 (zh) * 2024-02-01 2025-08-07 山东先声生物制药有限公司 吲哚衍生物作为ras抑制剂及其应用
WO2025214350A1 (en) * 2024-04-08 2025-10-16 Sunrise Oncology (Hong Kong) Limited Macrocyclic compounds as ras inhibitors for the treatment of cancer
WO2026046393A1 (zh) * 2024-09-02 2026-03-05 山东先声再明生物制药有限公司 吲哚类衍生物的制备及其应用

Also Published As

Publication number Publication date
AU2019401466A1 (en) 2021-07-01
MX2021007468A (es) 2021-08-05
IL284210A (en) 2021-08-31
US20240139185A1 (en) 2024-05-02
KR20210116479A (ko) 2021-09-27
EP3897644A1 (en) 2021-10-27
IL284210B2 (en) 2025-05-01
TW202600561A (zh) 2026-01-01
SG11202106605VA (en) 2021-07-29
BR112021012057A2 (pt) 2021-10-19
WO2020132597A8 (en) 2020-07-16
AU2025205500A1 (en) 2025-07-31
AU2019401466B2 (en) 2025-04-24
JP7721052B2 (ja) 2025-08-12
EP3897644A4 (en) 2022-09-07
JP2025037925A (ja) 2025-03-18
SA521422304B1 (ar) 2023-12-21
IL284210B1 (en) 2025-01-01
CA3123869A1 (en) 2020-06-25
IL317393A (en) 2025-02-01
US20200197391A1 (en) 2020-06-25
TW202039509A (zh) 2020-11-01
MX2025001810A (es) 2025-03-07
JP2022520154A (ja) 2022-03-29
WO2020132597A1 (en) 2020-06-25

Similar Documents

Publication Publication Date Title
CN119462822B (zh) Ras抑制剂
CN115873020B (zh) Ras抑制剂
US20240139185A1 (en) Compounds that participate in cooperative binding and uses thereof
AU2022270116A1 (en) Ras inhibitors
CN118922423A (zh) Ras抑制剂
WO2024211663A9 (en) Macrocyclic ras inhibitors
WO2024211712A1 (en) Condensed macrocyclic compounds as ras inhibitors
TWI917313B (zh) 參與協同結合之化合物及其用途
RU2858913C2 (ru) Соединения, которые участвуют в кооперативном связывании, и их применение
HK40076306A (en) Ras inhibitors

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination